First U.S. Avastin and Herceptin Biosimilars

First U.S. Avastin and Herceptin Biosimilars


On Thursday, July 13, 2017, FDA's Oncological Drugs Advisory Committee unanimously recommended approval of biosimilars of two blockbuster cancer drugs. The first, Amgen and Allergan's ABP-215 , is a proposed biosimilar of Roche/Genentech's Avastin , a monoclonal antibody used in the treatment of a number of different cancers.



from Biotech News